MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yin, D.
Right arrow Articles by Dalton, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yin, D.
Right arrow Articles by Dalton, J. T.

Vol. 63, Issue 1, 211-223, January 2003

Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor

Donghua Yin, Yali He, Minoli A. Perera, Seoung Soo Hong, Craig Marhefka, Nina Stourman, Leonid Kirkovsky, Duane D. Miller, and James T. Dalton

Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio (D.Y., M.A.P., J.T.D.); and Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee, Memphis, Tennessee (Y.H., S.S.H., C.M., N.S., L.K., D.D.M.)

The purposes of the present studies were to examine the androgen receptor (AR) binding ability and in vitro functional activity of multiple series of nonsteroidal compounds derived from known antiandrogen pharmacophores and to investigate the structure-activity relationships (SARs) of these nonsteroidal compounds. The AR binding properties of sixty-five nonsteroidal compounds were assessed by a radioligand competitive binding assay with the use of cytosolic AR prepared from rat prostates. The AR agonist and antagonist activities of high-affinity ligands were determined by the ability of the ligand to regulate AR-mediated transcriptional activation in cultured CV-1 cells, using a cotransfection assay. Nonsteroidal compounds with diverse structural features demonstrated a wide range of binding affinity for the AR. Ten compounds, mainly from the bicalutamide-related series, showed a binding affinity superior to the structural pharmacophore from which they were derived. Several SARs regarding nonsteroidal AR binding were revealed from the binding data, including stereoisomeric conformation, steric effect, and electronic effect. The functional activity of high-affinity ligands ranged from antagonist to full agonist for the AR. Several structural features were found to be determinative of agonist and antagonist activities. The nonsteroidal AR agonists identified from the present studies provided a pool of candidates for further development of selective androgen receptor modulators (SARMs) for androgen therapy. Also, these studies uncovered or confirmed numerous important SARs governing AR binding and functional properties by nonsteroidal molecules, which would be valuable in the future structural optimization of SARMs.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. Jones, J. Chen, D. J. Hwang, D. D. Miller, and J. T. Dalton
Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro, 4-Chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception
Endocrinology, January 1, 2009; 150(1): 385 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
R. Narayanan, C. C. Coss, M. Yepuru, J. D. Kearbey, D. D. Miller, and J. T. Dalton
Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways
Mol. Endocrinol., November 1, 2008; 22(11): 2448 - 2465.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Chen, K. C. Ahn, N. A. Gee, M. I. Ahmed, A. J. Duleba, L. Zhao, S. J. Gee, B. D. Hammock, and B. L. Lasley
Triclocarban Enhances Testosterone Action: A New Type of Endocrine Disruptor?
Endocrinology, March 1, 2008; 149(3): 1173 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. H. Bisson, A. V. Cheltsov, N. Bruey-Sedano, B. Lin, J. Chen, N. Goldberger, L. T. May, A. Christopoulos, J. T. Dalton, P. M. Sexton, et al.
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
PNAS, July 17, 2007; 104(29): 11927 - 11932.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. E. Bohl, Z. Wu, D. D. Miller, C. E. Bell, and J. T. Dalton
Crystal Structure of the T877A Human Androgen Receptor Ligand-binding Domain Complexed to Cyproterone Acetate Provides Insight for Ligand-induced Conformational Changes and Structure-based Drug Design
J. Biol. Chem., May 4, 2007; 282(18): 13648 - 13655.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Yang, C. E. Bohl, V. A. Nair, S. M. Mustafa, S. S. Hong, D. D. Miller, and J. T. Dalton
Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 402 - 408.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Wu, Z. Wu, J. Yang, V. A. Nair, D. D. Miller, and J. T. Dalton
PHARMACOKINETICS AND METABOLISM OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR IN RATS: IMPLICATION OF MOLECULAR PROPERTIES AND INTENSIVE METABOLIC PROFILE TO INVESTIGATE IDEAL PHARMACOKINETIC CHARACTERISTICS OF A PROPANAMIDE IN PRECLINICAL STUDY
Drug Metab. Dispos., March 1, 2006; 34(3): 483 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Gao, Z. Wu, C. E. Bohl, J. Yang, D. D. Miller, and J. T. Dalton
CHARACTERIZATION OF THE IN VITRO METABOLISM OF SELECTIVE ANDROGEN RECEPTOR MODULATOR USING HUMAN, RAT, AND DOG LIVER ENZYME PREPARATIONS
Drug Metab. Dispos., February 1, 2006; 34(2): 243 - 253.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Chen, D. J. Hwang, K. Chung, C. E. Bohl, S. J. Fisher, D. D. Miller, and J. T. Dalton
In Vitro and in Vivo Structure-Activity Relationships of Novel Androgen Receptor Ligands with Multiple Substituents in the B-Ring
Endocrinology, December 1, 2005; 146(12): 5444 - 5454.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. E. Bohl, D. D. Miller, J. Chen, C. E. Bell, and J. T. Dalton
Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor
J. Biol. Chem., November 11, 2005; 280(45): 37747 - 37754.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Perakyla, M. Malinen, K.-H. Herzig, and C. Carlberg
Gene Regulatory Potential of Nonsteroidal Vitamin D Receptor Ligands
Mol. Endocrinol., August 1, 2005; 19(8): 2060 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
J. Chen, J. Kim, and J. T. Dalton
Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators
Mol. Interv., June 1, 2005; 5(3): 173 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. E. Bohl, W. Gao, D. D. Miller, C. E. Bell, and J. T. Dalton
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
PNAS, April 26, 2005; 102(17): 6201 - 6206.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Chen, D. J. Hwang, C. E. Bohl, D. D. Miller, and J. T. Dalton
A Selective Androgen Receptor Modulator for Hormonal Male Contraception
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 546 - 553.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. R. Brown
Nonsteroidal Selective Androgen Receptors Modulators (SARMs): Designer Androgens with Flexible Structures Provide Clinical Promise
Endocrinology, December 1, 2004; 145(12): 5417 - 5419.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow, D. D. Miller, and J. T. Dalton
Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5{alpha}-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia
Endocrinology, December 1, 2004; 145(12): 5420 - 5428.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Yin, H. Xu, Y. He, L. I. Kirkovsky, D. D. Miller, and J. T. Dalton
Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1323 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Yin, W. Gao, J. D. Kearbey, H. Xu, K. Chung, Y. He, C. A. Marhefka, K. A. Veverka, D. D. Miller, and J. T. Dalton
Pharmacodynamics of Selective Androgen Receptor Modulators
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1334 - 1340.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics